Abstract
The detrimental health effects of smoking are well-known, but the impact of long-term nicotine use without exposure to the other constituents of tobacco is less clear. Given the increasing long-term use of alternative nicotine delivery systems, such as e-cigarettes, it is increasingly important to understand and separate the effects of long-term nicotine use from the impact of tobacco smoke exposure. Using a multivariable Mendelian randomisation framework, we explored the direct effects of nicotine compared with the non-nicotine constituents of tobacco smoke on health outcomes (lung cancer, chronic obstructive pulmonary disease [COPD], forced expiratory volume in one second [FEV-1], forced vital capacity [FVC], coronary heart disease [CHD], and heart rate [HR]). The results suggest that these smoking-related outcomes are not due to nicotine exposure but are caused by the other components of tobacco smoke; however, there are multiple potential sources of bias, and the results should be triangulated using evidence from a range of methodologies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JNK, RCR, MRM, ES, and AET are all members of the Medical Research Council (MRC) Integrative Epidemiology Unit at the University of Bristol (MC_UU_00032/01, MC_UU_00032/04, MC_UU_00032/07). REW is funded by the Norwegian South-Eastern Regional Health Authority (2020024). This work was supported by Cancer Research UK (grant number C18281/A29019). This work is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was sought from the UK Biobank (project 9142). UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC). The REC reference for UK Biobank is 11/NW/0382. Further details about the ethics approval sought for data collection in UK Biobank can be found online (https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
In this revision, we amended our analyses after responses to our original pre-print. Rather than using cotinine as our main proxy for nicotine exposure (which can be impacted by metabolism and is unlikely to be on the causal pathway from genetic liability to health outcomes) we instead use the nicotine metabolite ratio which is more likely to be on the causal pathway. We have included the cotinine analyses as well as analyses with cotinine+3HC as sensitivity analyses. We provide a detailed explanation of why nicotine metabolite ratio was chosen to be the main proxy for nicotine exposure within the pre-print.
Data Availability
UK Biobank data is available at www.ukbiobank.ac.uk. GSCAN data is available at https://doi.org/10.13020/3b1n-ff32. The Cotinine Consortium data is available at https://doi.org/10.5523/bris.182rhz19hg3lz1172a7yfcap9v. The nicotine metabolite ratio and cotinine+3HC summary data are available on request from the authors and are available in their supplementary material (https://doi.org/10.1038/s41380-020-0702-z).
https://doi.org/10.13020/3b1n-ff32
